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Both lower urinary tract symptoms (LUTSs) and erectile dysfunction (ED) are highly prevalent, frequently
coassociated, and signiﬁcantly contribute to the overall quality of life. Numerous cross-sectional epide-
miological studies have reported a clear and clinically signiﬁcant association between LUTSs and ED in
aging men worldwide. LUTSs were also demonstrated to be an independent risk factor for ED after
controlling for age, comorbidities, and lifestyle factors. Four main pathophysiological mechanisms,
including the nitric oxide (NO)/NO synthase (NOS) theory, autonomic hyperactivity, the Rho-kinase
activation pathway, and pelvic atherosclerosis, currently support the relationship. New approaches
were recommended to evaluate and manage both conditions and select treatment options. In addition to
well-known treatment effects of a1-blockers and phosphodiesterase (PDE)-5 inhibitors, a1-blockers can
also be beneﬁcial in the treatment of ED, while PDE-5 inhibitors can be beneﬁcial in the treatment of
LUTSs. Combination therapy with both agents can improve LUTSs and/or ED via different mechanisms of
action. Testosterone replacement therapy (TRT) with or without PDE-5 inhibitors was also reported to
improve erectile function and LUTSs in hypogonadal men. Additional studies of combination therapy for
LUTSs, ED, and other comorbidities are needed to establish new approaches to achieve optimal
management of these conditions in aging men.
Copyright  2011, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Lower urinary tract symptoms (LUTSs) are comprised of non-
gender- and nonorgan-speciﬁc symptoms, which include storage,
voiding, and postmicturition symptoms.1 The primary cause of
LUTSs is benign prostatic hyperplasia (BPH) in men aged50 years.
Erectile dysfunction (ED) is deﬁned as the persistent inability to
achieve and maintain an erection sufﬁcient for satisfactory sexual
performance.2 The relationship between LUTSs and ED has received
increasing attention because both conditions are highly prevalent,
frequently coassociated in men in the same age group, and signif-
icantly contribute to the overall quality of life.3,4
A large body of epidemiological studies demonstrated consistent
and compelling evidence for a relationship between LUTSs and ED
in aging men using various measurement approaches in different
population samples worldwide.5e37 In multivariate analyses that
controlled for age, comorbidities (such as hypertension, diabetes,
dyslipidemia, and cardiovascular disease), and lifestyle factors, LUTSs
were clearly demonstrated to be an independent risk factor for ED.rtment of Surgery, Cardinal
ei 23137, Taiwan.
e.
ciation. Published by Elsevier TaiwAlthough the causal link between LUTSs and ED is not well
established, four main pathophysiological mechanismswith varying
degrees of overlap currently support the relationship. These include
the nitric oxide (NO)/NO synthase (NOS) theory, autonomic hyper-
activity, the Rho-kinase activation pathway, and pelvic atheroscle-
rosis.38 As a result of these associations, new approaches were
recommended to evaluate andmanage both conditions and to select
treatment options.
2. Epidemiological evidence
Numerous epidemiological studies investigated the association
between ED and LUTSs. Although most of these studies were cross-
sectional, they demonstrate consistently strong associations,
particularly with study consistency and dose-response effects.
2.1. Cross-sectional studies
Large-scale population- (Table 15e19), health screening-
(Table 220e23) and clinical-based (Table 324e30) cross-sectional
studies summarized here indicate a clear and clinically signiﬁcant
association between LUTSs and ED worldwide. In these studies
multivariate logistic regression analyses were used to determine
the independent effects of LUTSs on ED after controlling for age and
other known risk factors. When viewed together, LUTSs appear toan LLC. Open access under CC BY-NC-ND license.
Table 1
Population-based cross-sectional studies.
Study Study name or country
(sample)
Results
Laumann et al 19995 USA (n ¼ 1410) LUTSs were a signiﬁcant predictor for ED (OR, 3.13) after controlling for demographic and lifestyle
factors.
Martin-Morales et al 20016 Spain (n ¼ 2476) LUTSs were a signiﬁcant risk factor for ED (age-adjusted OR, 2.67).
Blanker et al 20017 Krimpen (n ¼ 1688) ORs of moderate and severe LUTSs for ED were 3.4 and 7.5, respectively.
Braun et al 20008 Cologne Male Survey
(n ¼ 4489)
LUTSs in 72.2% of men with ED vs. 37.7% without ED; the OR of LUTSs for ED was 2.11.
Boyle et al 20039 UrEpik study (n ¼ 4800) The OR of moderate/severe LUTSs for ED was 1.39.
Nicolosi et al 200310 4 countries (n ¼ 1335) ORs of moderate and severe LUTSs for ED were 2.19 and 4.91, respectively, in relatively healthy men.
Rosen et al 200311 MSAM-7 (n ¼ 12815) ORs of mild, moderate, and severe LUTSs for ED were 1.98, 3.76, and 7.67, respectively.
Hansen et al 200412 Denmark (n ¼ 3442) ORs of obstructive, irritative, and mixed LUTSs for ED were 2.07, 1.55, and 2.82, respectively.
Chung et al 200413 Olmsted County study
(n ¼ 1547)
Signiﬁcant correlation between LUTS severity and domain scores for ED after adjusting for age.
Laumann et al 200514 29 countries (n ¼ 11205) The OR of prostatic disease for ED was in the range 1.8e2.0.
Irwin et al 200815 EPIC study (n ¼ 502) Cases were signiﬁcantly more likely to have ED than were the controls (OR, 1.5).
Brookes et al 200816 BACH (n ¼ 2301) ED was signiﬁcantly associated with LUTSs after adjusting for age; may primarily be due to nocturia,
incontinence, and symptoms suggestive of prostatitis.
Wong et al 200917 China (n ¼ 1566) Moderate to severe LUTSs (OR, 1.63) were independently associated with increased risk of having ED.
Wein et al 200918 EpiLUTS (n ¼ 11834) Urgency with fear of leaking and leaking during sexual activity were signiﬁcantly associated with ED.
Morant et al 200919 UK (n ¼ 11327) ORs of storage, voiding, and both voiding and storage LUTSs for ED were 3.0, 2.6, and 4.0, respectively.
BACH ¼ Boston Area Community Health Survey; ED ¼ erectile dysfunction; LUTSs ¼ lower urinary tract symptoms; MSAM-7 ¼ Multinational Survey of the Aging Male;
OR ¼ odds ratio.
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1.39e7.67.
The dose-response effect is well demonstrated by the fact that
the severity of LUTSs is signiﬁcantly associated with the prevalence
and severity of ED.7,10,11,13,27 Men with severe LUTSs have a higher
OR for ED than do those with moderate LUTSs. The baseline data
from the placebo arm of the Proscar Long-term Efﬁcacy and Safety
Study (PLESS)28 reported that every one-point increase in the LUTS
severity score was associated with a 2% increase in ED risk even
when controlling for age.
In addition, both storage and voiding LUTSs had signiﬁcant
associations with ED if LUTSs were separated into storage (irrita-
tive) and voiding (obstructive) LUTSs.12,19 However, another single-
center study reported that obstructive symptoms, not irritative
symptoms, were most highly correlated with ED. The data need to
be cautiously interpreted due to the small sample size of the study
(n ¼ 181).31 On the contrary, two Taiwanese studies demonstrated
that irritative symptoms were more related to ED.23,29 The
discrepancy may be explained by the different inclusion criteria
and adjusted cofactors. Further investigations are needed to clarify
the roles of storage and voiding LUTSs in the development of ED.
2.2. Longitudinal studies
The preponderance of well-designed longitudinal studies
highlights the cause-and-effect relationship. In contrast to
numerous cross-sectional studies, only a few longitudinal studies
have investigated the association between LUTSs and ED.
Shiri et al32 using population-based data obtained from 1126
Finnish men in the Tampere Aging Male Urological Study reported
that only incomplete emptying plus bother and overﬂow inconti-
nence plus bother were independent predictors of moderate/severeTable 2
Health screening-based cross-sectional studies.
Study Study name or country (sample) Results
Terai et al 200420 Japan (n ¼ 2084) ORs of moderate a
Ponholzer et al 200521 Austria (n ¼ 2858) The OR of overall m
were primarily res
Liu et al 200622 Taiwan (n ¼ 141) Men with moderat
Tsai et al 201023 Taiwan (n ¼ 339) Irritative symptom
ED ¼ erectile dysfunction; LUTSs ¼ lower urinary tract symptoms; OR ¼ odds ratio.ED after controlling for age and comorbiditieswith 5 years of follow-
up. Another study on 428 Brazilian men without ED at the baseline
reported that the adjusted relative risk of developing ED was 3.67
for thosewith self-reported BPH after a mean follow-up of 2 years.33
Longitudinal data from the PLESS study28 also demonstrated
a signiﬁcant association between a one-point decrease in the LUTS
severity score and a decrease in ED severity.
Wong et al34 reported that patients who had more severe LUTSs
at the baseline had increased odds of having more severe ED (OR,
1.86 and 95% conﬁdence interval (CI), 1.16e2.97 for mild LUTSs at
the baseline; OR, 2.95 and 95% CI, 1.81e4.81 for moderate LUTSs at
the baseline; and OR, 3.82 and CI, 2.00e7.27 for severe LUTSs at the
baseline). Mondul et al35 also reported that menwith severe LUTSs
had a statistically signiﬁcant 40% higher risk of developing subse-
quent ED than did men without LUTSs. The risk of ED increased
with an increasing LUTS severity (p< 0.0001). The Krimpen study36
reported that irritative LUTSs are one of the signiﬁcant determi-
nants of ED. All these data support a dose-response and temporal
relationship between baseline LUTS severity and ED development
during follow-up.
In contrast to several studies that support the temporality of
LUTSs as a risk factor for ED, studies reporting ED as a risk factor for
LUTSs are scant. Kok et al37 reported ED as a signiﬁcant determinant
for LUTSs using data from Krimpen’s study. More evidence is
needed to clarify if ED is associated with the development of LUTSs.
3. Possible mechanisms underlying the interaction between
LUTSs and ED
A series of hypotheses has been proposed to explain the exis-
tence of a common physiopathology for LUTSs and ED. Currently,
the relationship between LUTSs and ED is supported by fournd severe LUTSs for ED were 4.49 and 7.34, respectively.
oderate/severe LUTSs for ED was 2.2. Obstructive symptoms and nocturia
ponsible for the association.
e to severe LUTSs were more likely to have ED (age-adjusted OR, 3.27).
s had a more-signiﬁcant association with ED than did the obstructive symptoms.
Table 3
Clinically-based cross-sectional studies.
Study Study name or country (sample) Results
Frankel et al 199824 12 countries (n ¼ 1271 with LUTSs/BPH) A signiﬁcant positive association was found between ED and LUTSs after adjusting for age
Vallancien et al 200325 Five countries in Europe (n ¼ 927 with
LUTSs/BPH)
55% of patients with mild LUTSs and 70% with severe LUTSs had ED; the OR for ED was 1.94.
Hoesl et al 200526 Germany (n ¼ 8768 with LUTSs/BPH) Age-adjusted ED prevalences were 53%, 62%, and 71% in men with no/mild, moderate,
and severe ED, respectively.
El-Sakka et al 200527 Saudi Arabia (n ¼ 476 with ED) Signiﬁcant association between LUTS severity and ED severity.
Paick et al 200528 PLESS baseline (n ¼ 2981 with LUTSs/BPH) One-point increase in the IPSS was associated with a 2% increase in the ED risk.
Tsao et al 200829 Taiwan (n ¼ 398) A consistent inverse correlation was found between ED and LUTS severity across age groups.
Rosen et al 200930 BPH Registry (n ¼ 3084) Total IPSS and IPSS bother scores were independent predictors of ED.
ED ¼ erectile dysfunction; IPSS ¼ international prostatic symptom score; LUTSs ¼ lower urinary tract symptoms; OR ¼ odds ratio; PLESS ¼ PROscar Long-term Efﬁcacy and
Safety Study.
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(NO)/NO synthase (NOS) theory; (2) autonomic hyperactivity; (3)
the Rho-kinase activation pathway; and (4) pelvic atheroscle-
rosis.38 Risk factors for one are often risk factors for another, and
second messenger cascades ultimately leading to smooth muscle
contraction and relaxation of either prostatic/bladder neck tissue or
erectile tissue may overlap. Nevertheless, at the present time,
a common pathophysiology of LUTSs and ED is still speculative and
deserves further research.
3.1. NO/NOS theory
The NO system is well characterized as the main regulator of
penile corporal smooth muscle relaxation and resultant erection.39
NO activates soluble guanylate cyclase of smooth muscle cells,
which in turn increases cyclic (c)GMP. Increased cellular cGMP
is responsible for smooth muscle cell relaxation and resultant
tumescence.
The NO pathway is also reported to have a role in the control of
human prostatic smooth muscle activity and/or in secretary
neurotransmission.40 Nitrergic innervation has been demonstrated
to decrease in human BPH tissues compared to normal prostate
tissue,41 suggesting a potential role for NO in the pathophysiology
of BPH. Moreover, the human bladder neck is also innervated by
NOS-containing nerves, and their density is higher in the outlet
region than in other parts of the bladder.42
Furthermore, distinct soluble guanylate cyclase expression and
measurement of NO release suggested that the urothelium is also
a target structure of NO.43 Studies in animals also suggest that NO
plays a role in preventing bladder contractions that result in
bladder hyperactivity, as observed in LUTSs.44 Taken together, the
NO/NOS pathway may have an important regulatory role on lower
urinary tract function and erectile function.
3.2. Autonomic hyperactivity
The degree of smooth muscle relaxation is inﬂuenced by the
balance between sympathetic and parasympathetic tone. Auto-
nomic hyperactivity, which refers to the dysregulation of sympa-
thetic and parasympathetic tone, is a component of metabolic
syndrome. Increased sympathetic activity results in penile ﬂac-
cidity, and it antagonizes penile erection.4 Hypertension, obesity,
and hyperinsulinemia were all claimed to be associated with
increased sympathetic activity.45
Experiments on animal models showed that manipulation of
autonomic activity affects prostate growth and differentiation.46
Special strains of rats that are spontaneously hypertensive can
develop increased autonomic activity, prostate hyperplasia, and ED.
Brief aggressive treatment of their hypertension can improve their
ED.47 In a different model, hyperlipidemic rats developedsimultaneous prostatic enlargement, bladder overactivity, and ED
after being fed a high-fat diet.48
Autonomic hyperactivity was also reported to be signiﬁcantly
associated with the International Prostatic Symptom Score (IPSS)
and BPH impact index score.49 The prostate size was also signiﬁ-
cantly correlated withmarkers for autonomic hyperactivity, such as
increased serum norepinephrine levels and an abnormal hyper-
tensive response to tilt-table testing.49 However, it is yet unclear
whether the increase in LUTSs or ED is a consequence of an alter-
ation in the function of the bladder/penis itself leading to increased
central activation or the result of a central increase in sensitivity to
peripheral signals.43.3. The Rho-kinase activation pathway
RhoA, a small G-protein, and its downstream target, Rho-kinase,
are reported to be possible mediators of a-adrenergic- (norepi-
nephrine) and endothelin-1-triggered smooth muscle contrac-
tions.50 Thus, abnormal upregulation of the Rho-kinase pathway
could contribute to a lack of smooth muscle relaxation. Rho-kinase
activation may potentiate smooth muscle tone in the corpus cav-
ernosum of the rat via the use of norepinephrine and endothelin.51
Corpus cavernous smooth muscles from rabbits with partial
bladder outlet obstruction are reported to show increased penile
smooth muscle contractility, reduced relaxation, modest alter-
ations in total smooth muscle myosin, decreased innervation, and
increased smoothmuscle bundle size.52 Another study also showed
Rho-kinase dysfunction in the bladder following bladder outlet
obstruction.53 Thus, increased Rho-kinase activity might represent
a common link between LUTSs and ED.3.4. Pelvic atherosclerosis
Diffuse atherosclerosis of the prostate, penis, and bladder is
another hypothesis linking LUTSs with ED.54 Animal models of
hypercholesterolemia and pelvic ischemia show similar alterations
of smooth muscle in the bladder, prostate, and penis. Hypoxia-
induced overexpression of transforming growth factor (TGF)-b1
and altered prostanoid production are proposed as potential
mechanisms.
Bladder ischemia from either bladder outlet obstruction or
pelvic vascular disease can induce bladder smooth muscle loss and
collagen deposition, leading to loss of compliance, detrusor over-
activity, and impaired detrusor contractility. Prostate ischemia can
result in a less distensible urethra, which might also worsen LUTSs.
Moreover, penile ischemia might result in ED. Pelvic atheroscle-
rosis may be associated with metabolic syndrome, autonomic
hyperactivity, upregulated Rho-kinase activity, and reduced NOS
expression.38
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and ED
Aging, sex hormones, and growth factors are generally consid-
ered to play important roles in the pathogenesis of BPH.55 Although
few data describe the relationship between male LUTSs and sex
hormones are available, there are several plausible physiological
mechanisms to explain the inverse association of testosterone and
LUTSs. Autonomic nervous system overactivity may play a key role
in developing and increasing the severity of LUTSs. Others have
postulated the inﬂuence of testosterone on postsynaptic non-
genomic receptors, and NO-mediated bladder neck relaxation.56
Approximately 20% of ED patients have low serum testosterone
levels.57 Serum levels of testosterone are closely related to mani-
festations of other etiologic factors in ED, such as atherosclerotic
disease, diabetes mellitus, and metabolic syndrome, and an inverse
relationship exists between serum testosterone and the severity of
these symptoms.58 Consequently, testosterone is becoming recog-
nized as an important factor in ED. A large body of evidence from
experimental animal models suggests that androgens beneﬁcially
modulate numerous multiple cellular components in the corpus
cavernosum, leading to structural and functional integrity of penile
erections. It is thought that the primary action of androgens in
erectile function in the rat model is via stimulation of NO
synthesis.59
4. Treatment for LUTSs and ED
a1-Blockers are the most effective monotherapy for LUTSs
suggestive of BPH, while phosphodiesterase (PDE)-5 inhibitors are
the mainstay treatment for ED. In addition to well-known treat-
ment effects, a1-blockers can also be beneﬁcial in the treatment of
ED, while PDE-5 inhibitors can be beneﬁcial in the treatment of
LUTSs (Table 462,63,65e68,72).
4.1. a1-Blockers for ED
The actions of both a1-adrenoceptors and to a lesser extent, a2-
adrenoceptors on smooth muscle ﬁbers are functionally important
for controlling the contractile tone of erectile tissues.60 Hence,
there is a pharmacological rationale for a1-blockers playing a role
in facilitating penile erection by counteracting the contraction
(detumescence) of corpus cavernosum smooth muscle ﬁbers when
there is sexual stimulation. Supporting this theory, pharmacolog-
ical experiments conducted on isolated corpus cavernosum of
rabbits showed that the selective a1-blocker, alfuzosin, had direct
relaxant effects.61Table 4
Large-scale studies of treatment for both erectile dysfunction (ED) and lower urinary tra
Study Patients Medication
a1-Blockers
van Moorselaar et al 200562 2434 men with BPH Alfuzosin (10 mg qd
Kirby et al 200563 680 men with BPH Doxazosin (4 and 8
PDE-5 inhibitors (randomized placebo-controlled)
MaVary et al 200765 369 men with ED and LUTSs Sildenaﬁl (50e100
Stief et al 200866 222 men with LUTSs Vardenaﬁl (10 mg b
MacVary et al 200767 281 men with LUTSs Tadalaﬁl (5e20 mg
Roehrborn et al 200868 1058 men with LUTSs Tadalaﬁl (2.5, 5, 10,
Combination therapy
Kaplan et al 200772 62 men with LUTSs and ED Sildenaﬁl (25 mg) þ
BPH ¼ benign prostatic hyperplasia; IIEF ¼ international index of erectile function; IPSSEvidence for the beneﬁcial effects of a1-blockers on erectile
functionwas also obtained from studies in patients with BPH/LUTSs
associated with ED.62,63
4.2. PDE-5 inhibitors for LUTSs
Because NO was also found to mediate male prostatic and
urinary functions in multiple ways, there is increasing interest in
using PDE-5 inhibitors to treat concomitant LUTSs. Tinel et al64
identiﬁed PDE-5 messenger (m)RNA expression in the bladder,
followed by the urethra and prostate, conﬁrming that the expres-
sion of PDE-5 mRNA in tissues is generally held responsible for
LUTSs. They also reported that the inhibition of PDE-5 might
decrease obstruction by dilatation of the prostatic urethra and
bladder, with effects on the irritative symptoms of LUTSs associated
with BPH in rats.
Four randomized, placebo-controlled studies sought to eluci-
date the relationship between PDE-5 inhibitors and LUTSs using
sildenaﬁl, vardenaﬁl, and tadalaﬁl.65e68 Regardless of the PDE-5
inhibitor used, these studies generally showed an improvement
in IPSS scores, but without a signiﬁcant change in maximum
urinary ﬂow rates (Qmax). The effects of PDE-5 inhibitors on
storage symptoms seem to be more marked than on voiding
symptoms. However, there is still no direct comparison of the
efﬁcacies of PDE-5 inhibitors with a1-blockers.
4.3. Combined treatment with a1-blockers and PDE-5 inhibitors
An alternative management strategy for patients with both
LUTSs and ED would be to provide combination therapy with
agents that improve LUTSs and/or ED without adversely affecting
either condition. a1-Blockers and PDE-5 inhibitors are likely to act
via different mechanisms, thereby providing the rationale for
combining them to treat LUTSs and ED. Interaction studies
conﬁrmed that tadalaﬁl has only marginal effects on blood pressure
when coadministered with selective a1-blockers, such as alfuzo-
sin.69 However, caution is still advised by the US Food and Drug
Administration when PDE5 inhibitors are coadministered with
a-blocker therapy. In some patients, concomitant use of these two
drug classes can signiﬁcantly lower blood pressure leading to
symptomatic hypotension.
Patients should be stable on a-blocker therapy prior to initiating
PDE-5 inhibitors. Patients who demonstrate hemodynamic insta-
bility on a-blocker therapy alone are at increased risk of symp-
tomatic hypotension with concomitant use of PDE-5 inhibitors.
Even in patients who are stable on a-blocker therapy, PDE-5
inhibitors should be initiated at the lowest dose. In patientsct symptoms (LUTSs).
Results
) Signiﬁcantly improved rigidity of erection in men
with sexual dysfunction.
mg qd) Signiﬁcant improvements in each of the ﬁve IIEF
domains in men with ED.
mg qd) IPSS improvement of 6.32 vs. a placebo of 1.93.
id) IPSS improvement of 5.9 vs. a placebo of 3.6.
qd) IPSS improvement of 2.8 vs. a placebo of 1.2.
and 20 mg qd) IPSS signiﬁcantly improved with at least a 5-mg dose.
Alfuzosin (10 mg qd) Combination therapy superior than either agent alone.
¼ international prostatic symptom score.
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therapy should be initiated at the lowest dose. Stepwise increases
in the a-blocker dose may be associated with further lowering of
the blood pressure when taking a PDE5 inhibitor.
The safety of the concomitant use of PDE-5 inhibitors and a-
blockers may be affected by other variables, including intravascular
volume depletion and other antihypertensive drugs. Sildenaﬁl
resulted in transient decreases in supine blood pressure in healthy
volunteers (with mean maximum decreases of 8.4 (systolic)/
5.5 mmHg (diastolic)), and additional blood pressure reductions of
8mmHg systolic and 7mmHg diastolic were notedwhen combined
with antihypertensive medications. Patients older than 65 years,
with hepatic or severe renal impairment, and concomitant use of
potent cytochrome P450 3A4 inhibitors had higher risks than
healthy volunteers.70 Prolonged erections of more than 4 hours and
priapism (painful erections of longer than 6 hours in duration)
were also infrequently reported after taking PDE-5 inhibitors.
In addition, alfuzosin and tadalaﬁl show an additive relaxant
effect on human detrusor muscle, human prostate tissues, and the
human corpus cavernosum in vitro.71 A pilot clinical study also
suggested that daily intake of 10 mg of alfuzosin and 25 mg of
sildenaﬁl is well tolerated and may be more effective than mono-
therapy in improving LUTSs and ED.72 Further research is war-
ranted to establish the value of this combination therapy in LUTSs
and ED.
4.4. Testosterone replacement therapy for hypogonadal men with
ED and LUTSs
Late-onset hypogonadism is reported to be associated with ED.
Testosterone replacement therapy (TRT) with or without PDE-5
inhibitors can improve erectile function in hypogonadal men.73,74
Kalinchenko et al75 reported in a pilot study that testosterone
administration improved LUTS symptoms in men with late-onset
hypogonadism. The mean maximal bladder capacity and compli-
ance were also reported to have signiﬁcantly increased, and mean
detrusor pressure at Qmax to have signiﬁcantly decreased after
TRT.76 Another randomized controlled study also reported that TRT
resulted in signiﬁcantly decreased IPSS and improvements in the
Qmax and voided volume compared to the control group.77
However, all of these studies enrolled a small number of
patients, and the mechanism of action of testosterone on LUTSs is
still not well understood. It may be connected with or it may
parallel the effects of testosterone on penile tissues or the bladder
in hypogonadal men. Further basic or large clinical studies are
needed.
5. Conclusions
Both LUTSs and ED are highly prevalent in aging men. LUTSs are
an independent risk factor for ED even after controlling for age and
other known risk factors. Although four possible pathogeneses
were proposed to explain such a relationship, further studies are
needed to deﬁne the mechanism(s) underlying the association
between LUTSs and ED. Additional studies using combination
therapy for LUTSs, ED, and other age-associated comorbidities are
needed to establish new approaches to achieve optimal manage-
ment of these conditions in aging men.
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